Leerink initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “market perform” rating and a $24 price target. The stock closed at $22.75 on July 21.Read More
Roth Capital Partners resumed coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and $3 price target. The stock closed at $1.52 on Friday.
“In our opinion, Phase 1 data demonstrated Galectin’s GR-MD-02’s positive effect on NASH fibrosis biomarkers,” writes analyst Sa’ar Yaniv.Read More
Leerink Partners has launched coverage of Axovant Sciences (NYSE MKT:AXON) with an “outperform” rating and $22 price target. The stock closed at $13.15 on Monday.
“We see Axovant as a compelling risk/reward play with three key shots on goal for lead products: RVT-101 (5HT6 antagonist) and nelotanserin (5HT2a inverse agonist), and see long-term upside to the stock if just one of these – Alzheimer’s Disease (AD), Dementia with Lewy Bodies, or hallucinations in DLB/Parkinson’s Disease Dementia – were to succeed,” writes analyst Paul Mattels.Read More
Leerink Partners has launched coverage of American Renal Associates (NYSE:ARA) with an “outperform” rating and $33 price target. The stock closed at $27.71 on Friday.
“Our positive thesis contemplates a forward adjusted EBITDA (excluding non-controlling interest) growth rate of 13% (2015-2019 estimated CAGR) and is based on three growth pillars,” writes analyst Ana Gupte.Read More
Rodman & Renshaw has initiated coverage of Presbia PLC (NASDAQ:LENS) with the “buy” rating and 18-month price target of $14. The stock closed at $3.90 on Tuesday.
Presbia has a novel corneal inlay product, the Flexivue Microlens, aimed at treating presbyopia, or nearsightedness.Read More